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Dear editor,
Animal experiments are vitally important for evaluation of
newly developed nuclear tracers for imaging and therapy of
cancers and cannot (yet) be adequately replaced. We have the
ethical responsibility to keep the number of animals and level
of discomfort to a minimum, but at the same time, we aim at
generating preclinical data with maximum validity and statis-
tical significance. The best way to balance these aspects is to
design and perform these experiments well. However, a closer
look at the current literature in the field of radiopharmaceutical
development reveals a plethora of flaws and inconsistencies in
the design and execution of preclinical animal experiments,
challenging what we aim for most, i.e., validity of our data as
an indispensable basis for clinical translation.
The validity of preclinical animal data is primarily defined
by (A) the choice of an animal model with maximum achiev-
able similarity in biology and symptoms with the human dis-
ease and (B) the choice of realistic, clinically translatable ex-
perimental conditions (e.g., dose regimens) [1]. Both aspects,
in our opinion, are oftentimes not sufficiently well implement-
ed, and we have written this letter to sharpen the awareness of
the radiopharmaceutical research community for the existing
bias in animal experiments and for the pitfalls leading to it.
With due regard to our own areas of expertise, we explicitly
limit the scope of our reflections to mouse models in nuclear
oncology.
In this research area, it is particularly important to differen-
tiate between the “natural” bias that is inherently connected
with using mouse tumor models, and the bias that is intro-
duced by choosing an inappropriate model for the evaluation
of a novel radiopharmaceutical.
As to the first aspect, it is evident that a model, per def-
inition, cannot be a perfect replication of the clinical condi-
tion [2]. We will always have to carefully consider the
existing and undebatable (and sometimes unavoidable) dif-
ferences betweenmice andmen, with particular focus on the
species dependence of (physiological) target expression as
well as on a potential, sometimes very pronounced species
selectivity of targeted tracers—a major source of bias in the
interpretation of biodistribution data. Nonetheless, ongoing
efforts are directed towards mimicking the development and
biology of human cancers as closely as possible, and the
researcher has the agony of choice between increasingly
sophisticated syngeneic mouse tumor models, (human)
cell-derived xenograft models and patient-derived xeno-
graft (PDX) models. Each of them has their respective ad-
vantages and disadvantages with respect to their ability to
reflect human disease as well as concerning their predictive
value, ease of use, and cost-effectiveness [2]. These general
issues invariably need to be taken into account and reviewed
critically when selecting one or the other model for a given
animal experiment in oncology.
However, preclinical radiopharmaceutical research is usu-
ally centered on tracer evaluation rather than target evaluation
as in, e.g., classical oncological fundamental research studies
trying to elucidate the role of a given molecular component in
tumor biology or as a target for novel therapeutics. This entails
a slightly different angle of view concerning the selection of
an “appropriate” tumor model, and in this letter, we try to draw
attention to some, in our opinion, crucial factors that challenge
the validity of animal experiments in current nuclear oncology
practice.
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For example, it is widely established and generally accept-
ed to use subcutaneous (human) xenograft models for tracer
evaluation. In this context, validity of the resulting in vivo data
is in large part determined by the target expression level on the
cell line used for the induction of tumor growth. There is a vast
spectrum of human or murine cancer cell lines available,
which, being derived from actual tumors, by nature display
realistic target expression levels and provide uptake data that
allow a relatively accurate anticipation of tracer performance
in patients, such as LNCaP prostate cancer cells for the eval-
uation for PSMA-targeted tracers. Nevertheless, there is a ten-
dency towards employing transfected cell lines displaying 10-
to 20-fold higher target expression (e.g., PC3 PIP in PSMA
research). Of course, this generates eye-catchingly high abso-
lute tumor uptake and striking tumor/non-tumor ratios, but
generates data with no true predictive value for the human
situation and leads to an overestimation of tracer performance
[3, 4]. This issue has also been critically addressed in the
context of the evaluation of novel 18F-labeled MCR1-
targeted imaging agents [5] in a subcutaneous melanoma
model with realistic MCR1 expression (human SK-MEL-1
cells with 1000 receptors/cell) compared with the historically
used B16-F10 murine melanoma model (22.000 receptors/
cell). Using two alternative 18F-labeled peptides with similar
MCR1-affinity, but different molar activities (79 vs 193MBq/
nmol), the authors impressively demonstrate that tracer
optimization is the key to a sensitive detection of low-level
target expression. Since the sensitivity of target detection is a
direct function of target expression, tracer affinity, and
injected dose (molar activity), our efforts should be focused
on optimizing tracers in these latter two respects. Furthermore,
the use of “unrealistic” tumor models, unduly shifting the
balance towards an apparent high sensitivity, should be aban-
doned for the sake of sincere tracer assessment.
Another aspect worth considering in this context is the
currently established and accepted practice of investigating
the influence of molar activity on tracer accumulation in target
vs non-target tissues by injecting the tracer at a wide range of
molar activities. When evaluating antibody-based tracers, this
dose-finding process may be justified, although one might
argue that the predictive value of these oftentimes extensive
(> 40 mice) studies for clinical translation is highly limited,
given the additional need for individual dose finding in clini-
cal studies. Thus, for the sake of reducing animal numbers and
based on the vast body of data already existing on radiolabeled
antibodies, injecting 2–3 standard doses may also be sufficient
for assessing the targeting performance of a given tracer.
Especially in the case of small-targeted agents such as
PSMA ligands, however, PET dose-escalation studies are of-
tentimes performed solely on the grounds of generating opti-
mal visual enhancement of tumor accumulation compared
with PSMA-mediated kidney uptake—with the injected li-
gand doses mostly lying in a range with virtually no relation
to clinically injectable doses [6]. For example, injection of
0.18 nmol of ligand (“intermediate molar activity”) in a 25-g
mouse corresponds to 540 nmol (~ 550 μg, depending on the
tracer used) in a 75 kg patient—a ligand dose beyond those
used for PSMA-targeted radioligand therapy (~ 200 μg). At
“low molar activities,” where tumor/kidney ratios finally
reach values > 1, ligand amounts of 4.8–6 mg/patient are
reached. This obvious lack of translatability of data and the
inherent bias in these studies should, in our opinion, strongly
encourage researchers in our field to critically reevaluate this
current practice.
Another example, where metrics are in blatant disfavor of
data validity, is the concept of radioligand therapy in mouse
models. In therapy studies, the relevant parameter of observa-
tion is, by definition, the therapeutic efficiency of a given
radiotracer. This, in turn, is determined by the dose deposited
in the tumor—which, when considering the currently used
protocols, is subject to substantial bias, just looking at simple
mathematics: A tumor with 6mmdiameter (~ 1 g) represents a
small tumor in a human and constitutes in average 1/75000 of
the total body weight (TBW). In a mouse, the same tumor—
and tumors frequently reach that size in therapy studies—
corresponds to 1/25 of TBW. In humans, standard adminis-
tered doses of, e.g., [177Lu]Lu-DOTA-TATE or [177Lu]Lu-
PSMA-617 are in the range of 7.4 GBq/patient, corresponding
to ~ 0.1 MBq/g body weight. Mice are injected with 30 MBq,
leading to a more than tenfold higher ratio of activity/gram
body weight, i.e., > 1 MBq/g. Given this substantial
“overdosing” of mice compared with the human situation, it
is not surprising that almost any radioligand therapy treatment
has some effect on survival in mice, an outcome that is
expected—and strongly biased. This, in our view, generally
challenges the usefulness of radioligand therapy studies in
mice, especially in the light of the excellent and constantly
improving dosimetry extrapolations from mice to humans.
Representative mouse biodistribution studies (applying realis-
tic tracer doses) allow us to generate initial dosimetry data
with good congruence with the human situation, and subse-
quent individual patient dosimetry, applying the therapeutic
tracer at a low dose (< 185 MBq), provides much more valu-
able information on whole body dosimetry and the expected
therapeutic efficiency of a given tracer than mouse therapy
studies will ever do. We thus suggest to critically question
our established workflows and to adjust them accordingly,
driven as much by ethical considerations as by the desire to
produce valid and valuable data.
In summary, we are well aware that all those involved in
preclinical tracer development are doing their best for gener-
ating valid data with translational relevance. However, we do
see room for improvement, not only on the experimental level
but also on the level of peer review and Editorial Offices as
well as Nuclear Medicine Societies. The community would
certainly profit from a sharpened awareness concerning the
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“sense and nonsense” in our current practice of conducting
animal experiments, including more critical review of obvious
inconsistencies in the experimental setup and stricter quality
control before publication. Moreover, a certain degree of har-
monization concerning “approved” tumor models with realis-
tic target expression or translatable tracer doses/molar activi-
ties, at least for one given molecular target, would greatly
support a better comparability between data from different
groups. And ultimately, it would allow us to reduce the num-
ber of bias “traps” on our way towards translating our devel-
opments into the clinic for the benefit of our patients.
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